scispace - formally typeset
A

Alain Fischer

Researcher at Collège de France

Publications -  28
Citations -  2319

Alain Fischer is an academic researcher from Collège de France. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Autoimmune lymphoproliferative syndrome. The author has an hindex of 15, co-authored 28 publications receiving 2000 citations. Previous affiliations of Alain Fischer include Boston Children's Hospital & University of Debrecen.

Papers
More filters
Journal ArticleDOI

Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

Luyan Liu, +70 more
TL;DR: Whole-exome sequencing reveals activating STAT1 mutations in some patients with autosomal dominant chronic mucocutaneous candidiasis disease.
Journal ArticleDOI

A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency

TL;DR: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1 and the long-term effect of this therapy on leukemogenesis remains unknown.
Journal ArticleDOI

The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008.

TL;DR: Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID, and the prevalence and incidence of PID remains a key question to be answered.
Journal ArticleDOI

Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies

TL;DR: All types of PIDs were associated with a risk of autoimmune and inflammatory complications, although the greatest risk was associated with T‐cell PIDs and common variable immunodeficiency.
Journal ArticleDOI

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry

Maria Elena Maccari, +81 more
TL;DR: The European Society for Immunodeficiencies (ESID)-APDS registry as discussed by the authors provides a comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.